Acquired firm has over 2,800 products related to reference standards and materials.

Sigma-Aldrich acquired all outstanding shares of Cerilliant of Round Rock, TX, to strengthen its analytical chemistry product portfolio. Cerilliant supplies reference standards and materials, products that support the clinical diagnostics, clinical toxicology, environmental, forensic, nutraceutical, and pharmaceutical markets.

Sigma-Aldrich expects this acquisition to be neutral to mildly accretive to earnings per share in 2011. Cerilliant reportedly has over 2,800 products and more than 30 years of expertise in the design, development, synthesis, characterization, and packaging of analytical standards, calibrators, controls, and certified reference materials.

Cerilliant employs 65 people at its laboratory and manufacturing facility in Round Rock. The company sustains a modern, robust quality system that incorporates cGMP, GLP, and ISO requirements. Cerilliant is accredited to ISO Guide 34 as well as ISO/IEC 17025 and is certified to ISO 9001:2008. Its capabilities complement Sigma-Aldrich’s existing Fluka® and Supelco® analytical brands and will expand the company’s analytical customer base and markets.

“Cerilliant’s strong product suite and solid relationships with customers and analytical equipment suppliers will bring important new business opportunities to our company’s analytical arena,” comments Russel Gant, vp of the analytical research business at Sigma-Aldrich. “Their experienced team and capabilities combined with the quality and breadth of our current analytical brands, our broad scientific knowledge, and our powerful global footprint will provide analytical customers around the globe with access to a broad and ever-increasing range of specialized, high-quality analytical standards from a convenient and reliable single source.”

Sigma-Aldrich’s last takeover came in March 2010 when it bought Ace Animals. The firm offered research rodents and contract breeding services, thus padding Sigma Advanced Genetic Engineering (SAGE™) Labs.

Previous articleSecond Phase III CF Trial Fails to Confirm Benefits of Inspire’s Denufosol Therapy
Next articleGenocea Pockets $35M to Progress Preclinical T-Cell Vaccines